机构称创新药产业链基本面已开始改善，关注恒生创新药ETF（159316）、创新药ETF易方达（516080）等投资价值

Core Insights - The innovation drug sector indices, including the CSI Innovation Drug Industry Index and the CSI Biotechnology Theme Index, experienced a decline of 1.0% as of the market close, indicating a short-term adjustment in the market [1] - Despite the recent downturn, the innovation drug sector is showing improved resilience, with positive trends observed in investment and financing data, orders, and performance metrics [1] Group 1: Index Performance - The CSI Innovation Drug Industry Index fell by 1.0% with a rolling P/E ratio of 50.5 times and a valuation increase of 73.4% since its inception [5] - The CSI Biotechnology Theme Index also decreased by 1.0%, having a rolling P/E ratio of 55.4 times and a valuation increase of 65.3% since its launch [7] - The CSI 300 Healthcare Index declined by 0.7%, with a rolling P/E ratio of 31.0 times and a valuation increase of 47.2% since its inception [9] Group 2: Sector Focus - The CSI Innovation Drug Industry Index focuses on leading companies in the A-share market involved in innovative drug research and development, comprising no more than 50 stocks [4] - The CSI Biotechnology Theme Index targets leading companies in the A-share market engaged in genetic diagnostics, biopharmaceuticals, blood products, and other human biotechnology sectors [6] - The CSI 300 Healthcare Index encompasses leading companies in the A-share healthcare sector, covering various segments such as chemical pharmaceuticals, medical services, and medical devices [8]